Skip to main content

Table 1 Clinical and CMR data of healthy subjects and patients with cardiomyopathies

From: Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis

Parameters Heathy subjects (n = 19) Dilated cardiomyopathy (n = 212) Hypertrophic cardiomyopathy (n = 34) Cardiac amyloidosis (n = 30) p-values*
Clinical and demographic data
 Age 30 ± 7 53 ± 18 58 ± 14 69 ± 12  < 0.001
 Female gender; n (%) 8 (42%) 87 (41%) 16 (47%) 12 (40%) NS
 Arterial hypertension 0 (0%) 93 (44%) 28 (82%) 19 (63%)  < 0.001
 Hyperlipidemia 0 (0%) 70 (33%) 16 (47%) 14 (47%) 0.02
 Diabetes mellitus 0 (0%) 26 (12%) 8 (24%) 4 (13%) NS
 Atrial fibrillation 0 (0%) 22 (10%) 3 (9%) 11 (37%)  < 0.001
 Left bundle branch block 0 (0%) 20 (9%) 3 (9%) 0 (0%) NS
 Body mass index (kg/m2) 23 ± 7 26 ± 5 29 ± 5 26 ± 3 0.01
 NYHA class NA 2.1 ± 0.8 2.3 ± 0.7 2.7 ± 0.6 0.001
Baseline CMR data
 LVEF (%) 60.1 ± 5.2 48.0 ± 13.2 55.9 ± 9.1 47.6 ± 10.2 0.002
 LV End-diastolic volume (ml) 137 ± 27 190 ± 27 166 ± 41 175 ± 40 NS
 LV End-diastolic volume index (ml/m2) 76 ± 12 95 ± 34 81 ± 17 88 ± 20  < 0.05
 LV End-systolic volume (ml) 54 ± 14 103 ± 72 73 ± 31 94 ± 35  < 0.05
 LV End-systolic volume index (ml/m2) 30 ± 7 52 ± 34 36 ± 14 47 ± 18  < 0.05
 LV Stroke volume (ml) 84 ± 15 86 ± 22 93 ± 23 82 ± 20 NS
 LV Stroke volume index (ml/m2) 47 ± 7 44 ± 10 46 ± 10 41 ± 10 NS
 Septal wall thickness (mm) 7.4 ± 1.7 9.5 ± 2.5 17.3 ± 6.1 16.0 ± 2.8  < 0.001
 Infero-lateral wall thickness (mm) 5.2 ± 1.4 6.9 ± 1.8 8.9 ± 3.0 11.7 ± 3.6  < 0.001
 LV mass (g) 75 ± 12 119 ± 39 160 ± 48 175 ± 51  < 0.001
 LV mass index (g/m2) 42 ± 7 60 ± 17 78 ± 19 88 ± 24  < 0.001
 MAPSE (mm) 13 ± 3 10 ± 3 9 ± 2 7 ± 3  < 0.001
 RVEF (%) 57.7 ± 4.5 52.2 ± 10.1 58.1 ± 6.6 49.2 ± 12.3 0.001
 TAPSE (mm) 24 ± 6 21 ± 6 21 ± 6 17 ± 5 0.001
 Ascending aorta (mm) 22 ± 3 30 ± 6 33 ± 5 35 ± 4  < 0.001
 Aortic arch (mm) 17 ± 2 23 ± 3 25 ± 4 26 ± 3  < 0.001
 Descending aorta (mm) 17 ± 2 22 ± 3 24 ± 4 25 ± 4  < 0.001
 Left atrial diameter (mm) 27 ± 4 37 ± 9 41 ± 9 43 ± 10  < 0.001
 Left atrial area index (cm2/m2) 11 ± 2 14 ± 3 15 ± 6 16 ± 4  < 0.001
 Pulmonary trunk diameter (mm) 22 ± 2 26 ± 4 26 ± 3 29 ± 4  < 0.01
  Wall motion score index 1.0 ± 0.0 1.4 ± 0.5 1.2 ± 0.5 1.6 ± 0.5 0.01
 %non-infarct related LGE segments 0 20 ± 19 22 ± 12 66 ± 43  < 0.001
CMR global strain data
 LV global longitudinal strain (%) − 21.3 ± 1.3 − 17.2 ± 3.8 − 15.4 ± 3.3 − 12.1 ± 4.1  < 0.001
 LV global circumferential strain (%) − 20.5 ± 1.1 − 17.2 ± 3.0 − 16.4 ± 2.0 − 14.0 ± 2.8  < 0.001
 RV global longitudinal strain (%) − 21.2 ± 1.1 − 18.8 ± 2.8 − 17.7 ± 2.8 − 14.8 ± 4.0  < 0.001
 RV global circumferential strain (%) − 19.2 ± 1.3 − 16.8 ± 3.0 − 15.7 ± 1.7 − 13.6 ± 3.4  < 0.001
  1. *p-values are reported for differences between patients with cardiomyopathies, excluding healthy subjects
  2. Data are presented as means ± standard deviations or as proportions. NA indicates not applicable; LVEF left ventricular ejection fraction, RVEF right ventricular ejection fraction, NYHA New York Heart Association, MAPSE mitral annular plane systolic excursion, TAPSE tricuspid annular plane systolic excursion